This product consists of the protease-cleavable linker MAL-di-EG-Val-Cit-PAB conjugated to the cytotoxic agent MMAE, forming a key component for constructing antibody-drug conjugates (ADCs). It is widely used in ADC research for targeted cancer therapy, facilitating both in vitro cytotoxicity studies and in vivo efficacy evaluations in preclinical models.